The management of women with chronic immune diseases, including inflammatory bowel disease, rheumatoid arthritis, and psoriasis, is often challenging. In September 2010, gastroenterologists, rheumatologists, dermatologists, and obstetricians convened for the second annual conference, “The Management of Women with Chronic Immune Disorders in the Era of Biologics.” Although the therapeutic options for these chronic diseases are similar across specialties, this meeting highlighted variations in patient management among the specialists present. Topics addressed included screening and monitoring, vaccinations, and specifically the use of the human papillomavirus vaccine, bone loss, the role of vitamin D, and care during pregnancy. The information presented at the meeting is summarized here to give the dermatology community a better understanding of how patients on similar medications are cared for in other specialties and to recognize areas of research needed in the field of dermatology.
WasanS.K., BakerS.E., SkolnikP.R., FarrayeF.A.A practical guide to vaccinating the inflammatory bowel disease patient. Am J Gastroenterol.2010; 105(6): 1231–8.
2.
LebwohlM., BagelJ., GelfandJ.M.From the Medical Board of the National Psoriasis Foundation: Monitoring and vaccinations in patients treated with biologics for psoriasis. J Am Acad Dermatol.2008; 58(1): 94–105.
3.
MelmedG.Y., IppolitiA.F., PapadakisK.A.Patients with inflammatory bowel disease are at risk for vaccine-preventable Illnesses. Am J Gastroenterol.2006; 101(8): 1834–40.
4.
SowdenE., MitchellW.S.An audit of influenza and pneumococcal vaccination in rheumatology outpatients. BMC Musculoskelet Disord.2007; 8: 58.
5.
RahierJ.F., Ben-HorinS., ChowersY.European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis.2009; 3(2): 47–91.
6.
PacheI., RoglerG., FelleyC.TNF-α blockers in inflammatory bowel diseases: practical consensus recommendations and a user's guide. Swiss Med Wkly.2009; 139(19-20): 278–87.
MelmedG.Y., AgarwalN., FrenckR.W.Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease. Am J Gastroenterol.2010; 105(1): 148–54.
9.
KapetanovicM.C., SaxneT., SjoholmA., TruedssonL., JonssonG., GeborekP.Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide in patients with rheumatoid arthritis. Rheumatology (Oxf).2006; 45(1): 106–11.
10.
ElkayamO., CaspiD., ReitblattT., CharboneauD., RubinsJ.B.The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum.2004; 33: 283–8.
11.
MeaseP.J., RitchlinC.T., MartinR.W.Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept. J Rheumatol.2004; 31(7): 1356–61.
12.
VillaL.L., AultK.A., GuilianoA.R., CostaR.L., PettaC.A., AndradeR.P.Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18. Vaccine.2006; 24: 5571–83.
13.
FDA Licensure of Bivalent Human Papillomavirus Vaccine(HPV2, Cervarix) for Use in Females and Updated HPV Vaccination Recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep.2010; 59(20): 626–9.
14.
EllerbrockT.V., ChiassonM.A., BushT.J.Incidence of cervical squamous intraepithelial lesions in HIV-infected women. JAMA.2000; 283: 1031–7.
15.
HeardI., TassieJ., SchmitzV., MandelbrotL., KazatchkineM.D., OrthG.Increased risk of cervical disease among human immunodeficiency virus-infected women with severe immunosuppresion and high human papillomavirus load. Obstet Gynecol.2000; 96: 403–9.
KaneS., KhatibiB., ReddyD.Higher incidence of abnormal Pap smears in women with inflammatory bowel disease. Am J Gastroenterol.2008; 103(3): 631–6.
18.
SinghH., DemersA.A., NugentZ., MahmudS.M., KliewerE.V., BernsteinC.N.Risk of cervical abnormalities in women with inflammatory bowel disease: a population-based nested case-control study. Gastroenterology.2009; 136: 451–8.
19.
BernsteinC.N., LeslieW.D., LeboffM.S.AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology.2003; 124(3): 795–841.
20.
KastR.E., AltschulerE.L.Bone density loss in Crohn's disease: role of TNF and potential for prevention by bupropion. Gut.2004; 53: 1055–8.
21.
di MunnoO., MazzantiniM., SinigagliaL.Effect of low dose methotrexate on bone density in women with rheumatoid arthritis: results from a multicenter cross-sectional study. J Rheumatol.2004; 31(7): 1305–9.
22.
MarotteH., Pallot-PradesB., GrangeL., GaudinP., AlexandreC., MiossecP.A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab. Arthritis Res Ther.2007; 9(3): R61.
23.
BernsteinM., IrwinS., GreenbergG.R.Maintenance infliximab treatment is associated with improved bone mineral density in patients with Crohn's disease. Am J Gastroenterol.2005; 100(9): 2031–5.
24.
MazzantiniM., Di MunnoO., SinigagliaL.Effect of cyclosporine A on bone density in female rheumatoid arthritis patients: results from a multicenter, cross-sectional study. Clin Exp Rheumatol.2007; 25(5): 709–15.
25.
HofbauerL.C., SchoppetM., ChristM., TeichmannJ., LangeU.Tumor necrosis factor-related apoptosis-inducing ligand and osteoprotegerin serum levels in psoriatic arthritis. Rheumatology (Oxf).2006; 45(10): 1218–22.
26.
DreiherJ., WeitzmanD., CohenA.D.Psoriasis and osteoporosis: a sex-specific association?J Invest Dermatol.2009; 129: 1643–9.
27.
AdoriniL.Immunomodulatory effects of vitamin D receptor ligands in autoimmune diseases. Int Immunopharmacol.2002; 2: 1017–28.
28.
SinghS., AibaS., ManomeH., TagamiH.The effects of dexamethasone, cyclosporine, and vitamin D3 on the activation of dendritic cells stimulated by haptens. Arch Dermatol Res.1999; 291: 548–54.
29.
Braun-MoscoviciY., ToledanoK., MarkovitsD., RozinA., NahirA.M., Balbir-GurmanA.Vitamin D level: is it related to disease activity in inflammatory joint disease?Rheumatol Int. DOI: 10.1007/s00296-009-1251–6. Published online December 23, 2009.
30.
KerrG.S., SabahiI., RichardsJ.S.Prevalence of vitamin D insufficiency/deficiency in rheumatoid arthritis and associations with disease severity and activity. J Rheumatol.2011; 38(1): 53–9.
31.
PappaH.M., GordonC.M., SaslowskyT.M.Vitamin D status in children and young adults with inflammatory bowel disease. Pediatrics.2006; 118(5): 1950–61.
32.
TurhanogluA.D., GülerH., YöndenZ., AslanF., MansurogluA., OzerC.The relationship between Vitamin D and disease activity and functional health status in rheumatoid arthritis. Rheumatol Int. doi: 10.1007/s00296-010-1393-6. Published online March 19, 2010.
33.
JosephA.J., GeorgeB., PulimoodA.B., SeshadriM.S., ChackoA.25 (OH) vitamin D level in Crohn's disease: association with sun exposure and disease activity. Indian J Med Res.2009; 130(2): 133–7.
34.
MihellerP., MuzesG., HritzI.Comparison of the effects of 1,25 dihydroxyvitamin D and 25 hydroxyvitamin D on bone pathology and disease activity in Crohn's disease patients. Inflamm Bowel Dis.2009; 15(11): 1656–62.
35.
AndjelkovicZ., VojinovicJ., PejnovicN.Disease modifying and immunomodulatory effects of high dose 1 alpha (OH) D3 in rheumatoid arthritis patients. Clin Exp Rheumatol.1999; 17(4): 453–6.
36.
GaalJ., LakosG., SzodorayP.Immunological and clinical effects of alphacalcidol in patients with psoriatic arthropathy: results of an open, follow-up pilot study. Acta Derm Venereol.2009; 89(2): 140–4.
37.
OsmancevicA., Landin-WilhelmsenK., LarköO., KrogstadA.L.Vitamin D status in psoriasis patients during different treatments with phototherapy. J Photochem Photobiol B.2010; 101(2): 117–23.
38.
Van de KerkhofP.C., WerfelT., HausteinU.F.Tacalcitol ointment in the treatment of psoriasis vulgaris: a multicentre, placebo-controlled, double-blind study on efficacy and safety. Br J Dermatol.1996; 135(5): 758–65.
39.
PrystowskyJ.H., MuzioP.J., SevranS., ClemensT.L.Effect of UVB phototherapy and oral calcitriol (1,25-dihydroxyvitamin D3) on vitamin D photosynthesis in patients with psoriasis. J Am Acad Dermatol.1996; 35: 690–5.
40.
MorimotoS., YoshikawaK., FukuoK.Inverse relation between severity of psoriasis and serum 1,25-dihydroxy-vitamin D level. J Dermatol Sci.1990; 1(4): 277–82.
41.
RyanC., MoranB., McKennaM.J.The effect of narrowband UV-B treatment for psoriasis on vitamin D status during wintertime in Ireland. Arch Dermatol.2010; 146(8): 836–42.
42.
AliY.M., KuriyaB., OrozcoC., CushJ.J., KeystoneE.C.Can tumor necrosis factor inhibitors be safely used in pregnancy?J Rheumatol.2010; 37(1): 9–17.
43.
CarterJ.D., LadhaniA., RiccaL.R., ValerianoJ., VaseyF.B.A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the food and drug administration database. J Rheumatol.2009; 36(3): 635–41.
44.
KatzJ.A., AntoniC., KeenanG.F., SmithD.E., JacobsS.J., LichtensteinG.R.Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol.2004; 99(12): 2385–92.
45.
VasiliauskasE.A., ChurchJ.A., SilvermanN., BarryM., TarganS.R., DubinskyM.C.Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol.2006; 4(10): 1255–8.
46.
KaneS., FordJ., CohenR., WagnerC.Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for crohn's disease before and after delivery. J Clin Gastroenterol.2009; 43(7): 613–6.
47.
MalekA., SagerR., KuhnP., NicolaidesK.H., SchneiderH.Evolution of maternofetal transport of immunoglobulins during human pregnancy. Am J Reprod Immunol.1996; 36(5): 248–55.
48.
StephensS., NesbittA., FoulkesR.Placental transfer of the anti-TNF antibody TN3 in rats: comparison of immunoglobulin G1 and pegylated FAB versions (abstract). Gut.2006; 55(suppl 7): A8.
49.
KaneS.V., AcquahL.A.Placental transport of immunoglobulins: a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy. Am J Gastroenterol.2009; 104(1): 228–33.
50.
PuigL., BarcoD., AlomarA.Treatment of psoriasis with anti-TNF drugs during pregnancy: case report and review of the literature. Dermatology.2010; 220(1): 71–6.
51.
CoelhoJ., BeaugerieL., ColombelJ.F., HébuterneX., LereboursE., LémannM.Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study. Gut.2011; 60(2): 198–203.
52.
GreavesM.W., DawberR.Azathioprine in psoriasis. BMJ.1970; 2(5703): 237–8.
53.
Du VivierA., MunroD.D., VerbovJ.Treatment of psoriasis with azathioprine. BMJ.1974; 1(5897): 49–51.
54.
KastR.E., AltschulerE.L.Remission of Crohn's disease on bupropion. Gastroenterology.2001; 121: 1260–1.
55.
KaneS., AltschulerE.L., KastR.E.Crohn's disease remission on bupropion. Gastroenterology.2003; 125(4): 1290.
56.
ModellJ.G., BoyceS., TaylorE., KatholiC.Treatment of atopic dermatitis and psoriasis vulgaris with bupropion-SR: a pilot study. Psychosom Med.2002; 64: 835–40.
